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Abstract
Background: Mupirocin is a topical antimicrobial agent which is used for the treatment of skin
and postoperative wound infections, and the prevention of nasal carriage of methicillin-resistant
Staphylococcus aureus (MRSA). However, the prevalence of mupirocin resistance in S. aureus,
particularly in MRSA, has increased with the extensive and widespread use of this agent in hospital
settings. This study characterized low- and high-level mupirocin-resistant S. aureus isolates obtained
from Nigeria and South Africa.
Methods: A total of 17 mupirocin-resistant S. aureus isolates obtained from two previous studies
in Nigeria and South Africa, were characterized by antibiogram, PCR-RFLP of the coagulase gene
and PFGE. High-level mupirocin resistant isolates were confirmed by PCR detection of the mupA
gene. The genetic location of the resistance determinants was established by curing and transfer
experiments.
Results: All the low-level mupirocin resistant isolates were MRSA and resistant to gentamicin,
tetracycline and trimethoprim. PFGE identified a major clone in two health care institutions located
in Durban and a health care facility in Pietermaritzburg, Greytown and Empangeni. Curing and
transfer experiments indicated that high-level mupirocin resistance was located on a 41.1 kb
plasmid in the South African strain (A15). Furthermore, the transfer of high-level mupirocin
resistance was demonstrated by the conjugative transfer of the 41.1 kb plasmid alone or with the
co-transfer of a plasmid encoding resistance to cadmium. The size of the mupirocin-resistance
encoding plasmid in the Nigerian strain (35 IBA) was approximately 35 kb.
Conclusion: The emergence of mupirocin-resistant S. aureus isolates in Nigeria and South Africa
should be of great concern to medical personnel in these countries. It is recommended that
methicillin-susceptible  S. aureus (MSSA) and MRSA should be routinely tested for mupirocin
resistance even in facilities where the agent is not administered. Urgent measures, including
judicious use of mupirocin, need to be taken to prevent clonal dissemination of the mupirocin/
methicillin resistant S. aureus in KZN, South Africa and the transfer of the conjugative plasmid
encoding high-level mupirocin resistance identified in this study.
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Background
The treatment of infections caused by antibiotic-resistant
bacteria especially methicillin-resistant Staphylococcus
aureus (MRSA) has become a worldwide problem in hos-
pital and community settings. Infection control pro-
grammes implement measures to contain the
dissemination of MRSA which include efforts to eradicate
carriage of S. aureus [1]. The antibiotic mupirocin used
topically has been shown to possess potent activity
against staphylococci and is used for the treatment of skin
and postoperative wound infections, and the prevention
of nasal carriage of MRSA [2,3]. However the widespread
use of mupirocin led to resistance in S. aureus, which has
been reported worldwide [4-9].
Mupirocin-resistant strains are divided into two groups:
low- and high-level resistance (MIC 8–256 and >256 mg/
L, respectively) [2]. In most cases, low-level resistance to
mupirocin is related to alterations in the host isoleucyl-
tRNA synthetase (IRS) [10,11]. Until recently, chromo-
somal mupirocin resistance was considered clinically
unimportant [2,12]. However, low-level mupirocin resist-
ance appears to be more prevalent in clinical isolates than
high-level resistance [13-15], and the emergence of low-
level mupirocin resistance has been shown to increase
failure rates for nasal decolonization of MRSA [16-18].
High-level mupirocin resistant strains cannot be eradi-
cated with mupirocin and constitute a serious clinical
problem, especially when they are resistant to methicillin
[19]. The clinical isolates exhibiting high-level resistance
to mupirocin contain two distinct IRS enzymes: endog-
enous IRS plus an additional IRS encoded by the mupA
gene [20], which is carried on plasmids that vary in size,
restriction patterns and their ability to be transferred in
conjugation experiments [4,20-23]. The mupA gene has
also been reported in the genomic DNA of a few S. aureus
isolates expressing low-level resistance, suggesting that the
mupA gene may be located in the chromosome [24,25].
Moreover, the chromosomal location of the mupA gene in
S. aureus expressing high-level mupirocin resistance has
been described [26].
The previous studies conducted by these investigators
indicated that the prevalence of S. aureus resistance to
mupirocin in South Africa and Nigeria was 7% and 0.5%
respectively [7,27]. This study reports on the phenotypic
and molecular characterization of mupirocin-resistant S.
aureus isolates in Nigeria and South Africa.
Methods
Antimicrobial susceptibility testing and PCR detection of 
the mupA gene
A total of 17 S. aureus isolates were investigated based on
their resistance to mupirocin from two studies on antibi-
otic susceptibility patterns of S. aureus obtained from clin-
ical samples in Nigeria and South Africa [7,27].
Susceptibility to various antibiotics was based on the disk
diffusion method according to the National Committee
for Clinical Laboratory Standards (now Clinical Labora-
tory Standards Institute) guidelines [28]. Susceptibility to
heavy metals (cadmium acetate, mercuric chloride) and
nucleic-acid binding compounds (ethidium bromide and
propamidine isethionate) was performed on the isolates
using disks prepared in the laboratory with the indicated
concentrations (10 μl): cadmium acetate (50 μg), propa-
midine isethionate (50 μg), mercuric chloride, (109 μg)
and ethidium bromide (60 μg). Interpretation of zone
diameters were considered as follows: ≤ 9 mm (resist-
ance), 10–12 mm (intermediate) for cadmium acetate; ≤
25 mm (resistance) for mercuric chloride; ≤ 10 mm
(resistance), 11–14 mm (intermediate) for propamidine
isethionate; and ≤ 9 mm (resistance), 10–14 mm (inter-
mediate) for ethidium bromide, as published previously
[29]. Minimum inhibitory concentration (MIC) of mupi-
rocin was determined using E-test strips (AB Biodisk,
Solna, Sweden) according to the manufacturer's instruc-
tions. The high-level mupirocin-resistant isolates (based
on the disk diffusion and E-test methods) were confirmed
by PCR detection of the mupA gene as described previ-
ously [7,27].
The low-level mupirocin-resistant isolates were obtained
from eleven wound samples and one isolate each from
blood, urine samples, and endotracheal aspirate. Further-
more, the high-level mupirocin-resistant isolate (A15)
from South Africa was obtained from a wound sample
while 35 IBA, the isolate from Nigeria was recovered from
a blood sample. Information on the source of the methi-
cillin-susceptible  S. aureus (MSSA) from South Africa
(P1929) was not available.
Plasmid DNA isolation
Plasmid DNA was isolated by the cetyl trimethyl ammo-
nium bromide method (CTAB) as earlier reported [30].
Plasmids were analysed by agarose (0.6% w/v) gel electro-
phoresis in 1 × TAE buffer (pH 7.2) at 25 V for 16 hr. The
Staphylococcus aureus strain WBG 4483, which has 4 plas-
mids (40.3 kb, 22.5 kb, 4.4 kb and 3.5 kb) served as the
plasmid molecular size standard. The approximate plas-
mid sizes (closed circular forms) were estimated by visual
inspection and using the GeneTools program (SynGene
Bioimaging System, Cambridge, United Kingdom).
Curing experiments
Two of the three high-level mupirocin-resistant isolates
(A15 – South Africa and 35 IBA – Nigeria) were selected
for curing and conjugation experiments based on their
antibiotic resistance profile. The mupirocin-resistant iso-
late P1929 from South Africa was not included in the
experiment because its antibiotic susceptibility patternBMC Infectious Diseases 2009, 9:10 http://www.biomedcentral.com/1471-2334/9/10
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was similar to 35 IBA. The loss of resistance determinants
(plasmids) was investigated as previously reported [31].
The isolates were subcultured on Brain Heart Infusion
Agar (BHIA, Biolab, South Africa) and incubated at
43.5°C for 24 hr. Sub-culturing on freshly prepared BHIA
was performed twice and incubated as stated above.
Thereafter, serial dilutions of the culture were plated on
BHIA plates, and incubated at 37°C for 24 and 48 hrs.
Single colonies were replica plated on BHIA plates as con-
trol and selection plates of BHIA containing mupirocin
(10 mg/L) and erythromycin (5 mg/L) for A15, and mupi-
rocin (10 mg/L) for 35 IBA. Single colonies which grew on
the control plate but did not grow on the selection plates
were noted and antibiotic susceptibility testing was per-
formed on them to verify loss of resistance. Thereafter,
colonies were screened for loss of the resistance determi-
nants by plasmid analysis and visualized after electro-
phoresis on 0.6% agarose gels. Cured strains (susceptible
to mupirocin) were confirmed for loss of resistance by a
negative result for the mupA gene by PCR.
Conjugation Experiments
Conjugation experiments were performed in Brain Heart
Infusion Broth (BHIB, Biolab, South Africa) with 40%
polyethylene glycol as previously reported [31]. Strains
A15 and 35 IBA were used as donors and S. aureus
WBG541 (fusidic and rifampicin-resistant) was the recip-
ient strain. Donor and recipients controls were set up with
each test. Transfer was considered to have occurred when
growth was observed on the selection plates from the
donor-recipient mixtures and not from the control exper-
iments. The transconjugants (using A15 as the donor
strain) were screened on BHIA plates containing mupi-
rocin (10 mg/L), and fusidic acid (5 mg/L); erythromycin
(5 mg/L) and fusidic acid (5 mg/L). Selections of
transconjugants for 35 IBA were made on BHIA contain-
ing mupirocin (10 mg/L) and fusidic acid (5 mg/L); tetra-
cycline (5 mg/L) and fusidic acid (5 mg/L). Transfer
frequency was expressed as the number of transconju-
gants per number of donor cells. Single colonies of
transconjugants were screened on BHIA containing
appropriate antibiotics by the replica plating method and
antibiotic susceptibility testing was performed on
transconjugants. Furthermore, the transconjugants were
screened to confirm plasmid content by agarose gel elec-
trophoresis. In addition, transconjugants exhibiting high-
level resistance to mupirocin were confirmed by the MIC
values and detection of the mupA gene.
PCR-RFLP of the coagulase gene
The 3' end region of the coagulase gene was amplified by
PCR and restriction fragment polymorphisms (RFLPs) of
the amplicons were determined by digestion with AluI
(Fermentas, UK) as previously described [7].
PFGE typing
PFGE typing of SmaI (Fermentas, UK) digested DNA was
carried out by a modification of the protocol previously
described [32]. The banding patterns were interpreted vis-
ually and strains showing the same PFGE pattern were
classified into pulsotypes using an alphabet (e.g. A, B, C
etc). Numeric sub-codes were used to represent < 3 band
difference (subtypes, e.g. A1, B1, etc) based on a previous
report [33].
Results
Resistance pattern of low and high-level mupirocin 
resistant S. aureus isolates to antimicrobial agents
The resistance profiles of the mupirocin-resistant S. aureus
isolates to various antimicrobial agents are presented in
Table 1. A total of 14 isolates from six health care institu-
tions in KZN, South Africa exhibited low-level resistance
to mupirocin (MIC: 8–24 mg/L). They were also resistant
to methicillin, gentamicin, tetracycline and trimethoprim.
A total of 12 low-level mupirocin resistant isolates were
resistant to erythromycin, 10 isolates were resistant to cip-
rofloxacin, and four isolates each were resistant to
rifampicin and chloramphenicol. Resistotyping revealed
that six low-level mupirocin resistant isolates expressed
resistance to cadmium acetate, propamidine isethionate,
mercuric chloride and ethidium bromide. Four isolates
were resistant only to mercuric chloride and two isolates
were resistant to cadmium acetate and mercuric chloride.
An MRSA isolate was susceptible to the heavy metals and
nucleic-acid binding compounds. The mupA gene was not
detected in the low-level mupirocin resistant strains while
the high-level mupirocin resistant isolates with MIC of
>1024 mg/L tested positive for the mupA gene. Further-
more, the high-level mupirocin-resistant isolates were
resistant to cadmium acetate but susceptible to mercuric
chloride and nucleic acid binding compounds (Table 1).
Genotyping (PCR-RFLP of the coagulase gene, PFGE) of 
low and high-level mupirocin resistant S. aureus strains
Molecular typing by PCR-RFLP of the coagulase gene
identified three RFLP patterns in the low- (81 bp, 567 bp;
325 bp, 405 bp and 81 bp, 324 bp, 405 bp) and high-level
(81 bp, 567 bp; 243 bp, 486 bp and 81 bp, 162 bp, 567
bp) mupirocin-resistant strains (Figure 1). PFGE identi-
fied two pulsotypes (A and B) among the low-level mupi-
rocin-resistant  S. aureus strains, and 10 of 14 strains
(71.4%) were classified in type A (Figure 2). The strains in
type A were observed in two health care institutions
located in Durban and a health care facility in Pietermar-
itzburg, Greytown and Empangeni, while type B was
noted in two health care institutions in Durban and in
Eshowe. Based on their PFGE patterns, the high-level
mupirocin-resistant strains from the two countries were
unrelated (Figure 3).BMC Infectious Diseases 2009, 9:10 http://www.biomedcentral.com/1471-2334/9/10
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Curing experiment
The isolates 35 IBA and A15 expressing high-level mupi-
rocin resistance were subjected to curing experiments as a
first step to determining the genetic location of their
resistance determinants. Results of the curing experiments
with 35 IBA showed that 6 of 293 colonies (2.0%)
screened for loss of resistance were susceptible to mupi-
rocin. Agarose gel electrophoresis indicated that this was
associated with the loss of c. 35 kb plasmid (Figure 4). Of
the 294 colonies screened on mupirocin and erythromy-
cin selection plates for A15, three and six colonies lost
resistance to erythromycin and mupirocin respectively.
Resistance to these antibiotics in the cured strains was lost
together with plasmids of c. 2.3 kb and 38 kb respectively
(Figure 4). The mupA gene was not detected in the cured
strains (susceptible to mupirocin) by PCR.
Conjugation experiment
Transconjugants were not observed on mupirocin selec-
tion plates when 35 IBA was used as the donor strain.
However, transconjugants were obtained on mupirocin
selection plates with A15 as the donor strain. Replica plat-
ing of 98 transconjugants on BHIA selection plates with
cadmium (5 mg/L), erythromycin (5 mg/L) and mupi-
rocin (10 mg/L) yielded one, three and 98 colonies respec-
tively. The susceptibility pattern of the parent and cured
Table 1: Characterization (antibiogram, PCR-RFLP of the coagulase gene and PFGE) of low and high-level mupirocin resistant S. 
aureus isolated in Nigeria and South Africa
Strain No Antibacterial 
resistance patterns
MUP MIC 
(mg/L)
mupA 
gene
Coagulase gene 
(± 20 bp)
PCR-RFLP 
Coagulase 
gene (bp)
PFGE 
type
A1 PEN, OX, GN, ERY, CHL, TET, TS, CIP, MU (L), Hg 12 - 800 324, 405 A
A2 PEN, OX, GN, TET, TS, RF, MU (L) 24 - 650 81, 567 B
A3 PEN, OX, GN, ERY, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb 16 - 850 324, 405 A
A4 PEN, OX, GN, TET, TS, RF, MU (L), Cad, Hg 24 - 650 81, 567 B
A5 PEN, OX, GN, ERY, CHL, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb 12 - 800 324, 405 A1
A6 PEN, OX, GN, ERY, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb 8 - 800 81, 324, 405 A
A7 PEN, OX, GN, ERY, TET, TS, RF, MU (L), Cad 24 - 650 81, 567 B1
A8 PEN, OX, GN, ERY, CHL, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb 8 - 800 81, 324, 405 A
A9 PEN, OX, GN, ERY, TET, TS, RF, MU (L), Cad, Hg 24 - 650 81, 567 B2
A10 PEN, OX, GN, ERY, CHL, TET, TS, CIP, MU (L), Hg 12 - 800 81, 324, 405 A
A11 PEN, OX, GN, ERY, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb 8 - 800 81, 324, 405 A
A12 PEN, OX, GN, ERY, TET, TS, CIP, MU (L), Hg 12 - 850 81, 324, 405 A2
A13 PEN, OX, GN, ERY, TET, TS, CIP, MU (L), Hg 8 - 800 81, 324, 405 A1
A14 PEN, OX, GN, ERY, TET, TS, CIP, MU (L), Cad, Pi, Hg, Eb 12 - 800 81, 324, 405 A
A15 PEN, OX, GN, ERY, TET, TS, RF, MU (H), Cad >1024 + 650 81, 567 B3
P1929 TM, TET, MU (H), Cad >1024 + 750 243, 486 C
35 IBA TET, MU (H), Cad >1024 + 800 81, 162, 567 D
KEY. PEN – Penicillin, OX – Oxacillin, GN – Gentamicin, ERY – Erythromycin, CHL – Chloramphenicol,
TET – Tetracycline, TS – Trimethoprim, RF – Rifamipicin, CIP – Ciprofloxacin,
MU (H) – High-level mupirocin resistance, MU (L) – Low-level mupirocin resistance
Heavy metals – Cad: Cadmium acetate; Hg: Mercuric chloride Nucleic acid binding compounds – Eb: Ethidium bromide; Pi: Propamidine isethionateBMC Infectious Diseases 2009, 9:10 http://www.biomedcentral.com/1471-2334/9/10
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strains along with the transconjugants are presented in
Table 2. The transfer frequency was calculated as 1.2 × 10-
5 and 2 × 10-8 for mupirocin and erythromycin resistance
determinants respectively. Transconjugants that were
resistant to mupirocin contained a single plasmid of c. 38
kb while those resistant to mupirocin and cadmium car-
ried two plasmids of c. 38 kb and 25 kb in size (Figure 5).
EcoRI restriction analysis showed that the plasmid in the
mupirocin-resistant transconjugant (TransMup) yielded
seven fragments (12.6, 10.9, 6.3, 4.8, 2.5, 2.3 and 1.7 kb)
indicating that the size of the mupirocin plasmid was 41.1
kb (Figure 6). The two plasmids in mupirocin and cad-
mium-resistant transconjugant (TransCad) produced nine
EcoRI fragments (17.3, 12.6, 10.9, 6.3, 4.8, 2.7, 2.5, 2.3,
1.7 kb) with seven fragments identical to those of the 41.1
kb plasmid in TransMup. The additional 17.3 and 2.7 kb
(20 kb) fragments were associated with the second plas-
mid carrying cadmium resistance in TransCad (Figure 6).
Discussion
This investigation studied mupirocin-resistant S. aureus
that were isolated in Nigeria and South Africa, using phe-
notypic and molecular methods. Clinical isolates of
mupirocin-resistant S. aureus was first reported in 1987
[34], and resistance has frequently been attributed to the
clinical use of mupirocin over extended periods [23] or in
areas of highly concentrated application, such as derma-
tology or burns units [35,36]. Mupirocin is prescribed and
administered for the treatment of MRSA infections and S.
aureus  nasal colonization among hospital patients in
PCR-RFLP of the coagulase gene in mupirocin-resistant  strains Figure 1
PCR-RFLP of the coagulase gene in mupirocin-resist-
ant strains. M: Molecular weight marker (100 bp). Lanes 1–
14: Low-level mupirocin resistant strains: A1–A14. Lanes 15–
17: High-level mupirocin-resistant strains: A15, P1929 (South 
Africa), 35 IBA (Nigeria).
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PFGE patterns of low-level mupirocin-resistant strains Figure 2
PFGE patterns of low-level mupirocin-resistant 
strains. M: Molecular weight standard S. aureus NCTC 8325. 
Lanes 1–14: A1–A14.
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PFGE patterns of high-level mupirocin-resistant strains from  Nigeria and South Africa Figure 3
PFGE patterns of high-level mupirocin-resistant 
strains from Nigeria and South Africa. M: Molecular 
weight standard S. aureus NCTC 8325; Lane 1: A15; Lane 2: 
P1929; Lane 3: 35 IBA
        1           M          2          3         M      
        kb 
         
            674 
         
           361 
           324 
            
            262 
         
            208 
            
           175 
          
           135 
            <80 
  B3                      C          D         BMC Infectious Diseases 2009, 9:10 http://www.biomedcentral.com/1471-2334/9/10
Page 6 of 9
(page number not for citation purposes)
KZN, and it appears that the extensive use of the agent in
health care institutions has contributed to the emerging
trend of S. aureus resistance. Typing based on phenotypic
and genotypic methods play an important role in under-
standing the epidemiology of MRSA and evaluating the
effectiveness of infection control and antimicrobial pre-
scribing measures [37]. In this study, two main PFGE
types (A and B) were identified among the low-level
mupirocin resistant strains obtained from six health care
institutions in the KZN province of South Africa. The
strains in pulsotype A were identified in two health care
institutions located in Durban and a health care facility in
Pietermaritzburg, Greytown and Empangeni, while pulso-
type B was noted in two health care institutions in Durban
and in Eshowe. Some degree of correlation was observed
with the three typing methods. The low-level mupirocin-
resistant strains with a PCR-RFLP pattern of 81, 567 bp
belonged to the clone B by PFGE typing. Moreover, MRSA
strains with PCR-RFLP pattern of 81, 324, 405 bp and
324, 405 bp had similar antibiotic resistance pattern and
belonged to the dominant clone A. Hence, this study has
demonstrated clonal dissemination of multiresistant
MRSA strains exhibiting low-level resistance to mupirocin
in health institutions in KZN province of South Africa.
The emergence and spread of low-level mupirocin-resist-
ant S. aureus should be of concern among health care
workers in South Africa because of recent reports on the
increase in treatment failure rates for nasal decolonization
of MRSA due to the emergence of low-level mupirocin
resistance [16-18].
Plasmid profiles of parent and cured strains Figure 4
Plasmid profiles of parent and cured strains: M: Molec-
ular weight marker (WBG 4483; Only closed circular DNA 
are labelled); Lanes 1–3: High-level mupirocin-resistant 
strains: Lane 1 – A15 (South Africa), Lane 2 – 35 IBA 
(Nigeria), Lane 3 – P1929 (South Africa); Lane 4: A15 parent 
strain; Lane 5 – A15cA (cured strain of A15 – resistant to 
mupirocin, susceptible to erythromycin – 38 kb plasmid 
encoding high-level mupirocin resistance); Lane 6 – A15cD 
(cured strain of A15 – susceptible to mupirocin, resistant to 
erythromycin – 2.3 kb plasmid); Lane 7 – 35 IBA parent (35 
kb plasmid encoding high-level mupirocin resistance); Lane 8 
– 35 IBA (CUR) – cured strain of 35 IBA (susceptible to 
mupirocin, resistant to tetracycline).
Mupirocin 
plasmid  
(c. 38kb) 
Mupirocin 
plasmid  
(c. 35kb) 
Erythromycin
plasmid  
(c. 2.3kb) 
Plasmid profile of transconjugants derived from the methicil- lin/mupirocin resistant S. aureus (strain A15) from South  Africa Figure 5
Plasmid profile of transconjugants derived from the 
methicillin/mupirocin resistant S. aureus (strain A15) 
from South Africa. M – WBG 4483 (only the closed circu-
lar forms of the plasmids are labelled); Lane 1 – TransMup 
(resistant to mupirocin); Lane 2 – TransCad (resistant to 
mupirocin and cadmium).BMC Infectious Diseases 2009, 9:10 http://www.biomedcentral.com/1471-2334/9/10
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Plasmid-mediated resistance to antimicrobial agents
among pathogenic bacteria constitutes a major clinical
and economic problem worldwide. In this study, the
genetic location of the high-level mupirocin resistance
determinant was resolved in two isolates by plasmid anal-
ysis, involving curing and conjugation experiments. Three
features were identified in the transfer experiments and
plasmid analysis. The first feature was the transfer of the
41.1 kb plasmid encoding high-level mupirocin resist-
ance. High-level mupirocin resistance has been found in
self-transmissible and non-self transmissible plasmids in
different countries [4,38-40], and this study has demon-
strated what appears to be the first report of a conjugative
mupirocin resistance plasmid in South Africa. The conju-
gative transfer of plasmids mediating high-level mupi-
rocin resistance may involve the co-transfer of small non-
conjugative plasmids encoding resistance to tetracycline
and chloramphenicol [22,23,40,41] and large plasmids
encoding resistance to penicillin [42]. The transfer of
resistance determinants mediating mupirocin and tri-
closan resistance in MRSA has also been reported [43].
The second feature was the conjugative transfer of a 41.1
kb plasmid mediating mupirocin resistance along with
the co-transfer of a plasmid encoding resistance to cad-
mium (Table 2; Figure 5). This observation suggests that
the 41.1 kb plasmid belong to a class of conjugative plas-
mids that could be co-transferred with other resistance
determinants. The third feature was the transfer of a 2.3 kb
plasmid mediating erythromycin resistance. Although our
observations on plasmid analysis and conjugation experi-
ments are preliminary due to the number of isolates stud-
ied, the demonstration of conjugative transfer of the
mupirocin resistance plasmid and its co-transfer with
other resistance plasmids clearly supports the judicious
use of this topical antibiotic in health institutions in
South Africa. Hence, urgent measures need to be taken to
prevent clonal dissemination of the mupirocin/methicil-
lin resistant S. aureus in KZN, South Africa. Future work
include investigating the nature of the plasmid encoding
mupirocin resistance in 35 IBA and P1929, the full
sequence and comparison of the mupA gene with other
sequences in the GenBank. This could probably provide
new insights on the evolution of the mupA  gene in S.
aureus.
Conclusion
This study has demonstrated the clonal dissemination of
multi-resistant MRSA strains exhibiting low-level resist-
ance to mupirocin in KZN and the emergence of high-
level mupirocin resistant S. aureus in Nigeria and South
Africa. Although the high-level mupirocin resistant S.
aureus strains from the two countries are genetically unre-
lated, the ability of the 41.1 kb mupirocin plasmid to
transfer the resistance determinant indicate the potential
for spread to mupirocin-susceptible MSSA and MRSA iso-
lates under the selective pressure of mupirocin. It is also
recommended that routine testing of MSSA and MRSA for
mupirocin resistance be conducted even in facilities where
mupirocin is not administered. This will facilitate the
early detection of resistance and assist in the control and
spread of mupirocin-resistant S. aureus.
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